Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 515, doi. 10.1007/s10637-016-0339-6
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2016 AND VI 34 AND IP 4
Results: 15
1
2
The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 399, doi. 10.1007/s10637-016-0345-8
- By:
- Publication type:
- Article
3
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 439, doi. 10.1007/s10637-016-0348-5
- By:
- Publication type:
- Article
4
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 497, doi. 10.1007/s10637-016-0349-4
- By:
- Publication type:
- Article
5
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR in non-small cell lung cancer cells.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 407, doi. 10.1007/s10637-016-0350-y
- By:
- Publication type:
- Article
6
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 450, doi. 10.1007/s10637-016-0351-x
- By:
- Publication type:
- Article
7
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 458, doi. 10.1007/s10637-016-0353-8
- By:
- Publication type:
- Article
8
Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 416, doi. 10.1007/s10637-016-0354-7
- By:
- Publication type:
- Article
9
Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 424, doi. 10.1007/s10637-016-0355-6
- By:
- Publication type:
- Article
10
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 468, doi. 10.1007/s10637-016-0356-5
- By:
- Publication type:
- Article
11
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 474, doi. 10.1007/s10637-016-0357-4
- By:
- Publication type:
- Article
12
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 522, doi. 10.1007/s10637-016-0362-7
- By:
- Publication type:
- Article
13
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 481, doi. 10.1007/s10637-016-0364-5
- By:
- Publication type:
- Article
14
Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design.
- Published in:
- 2016
- By:
- Publication type:
- Report
15
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 4, p. 490, doi. 10.1007/s10637-016-0365-4
- By:
- Publication type:
- Article